...
首页> 外文期刊>Reviews in Obstetrics and Gynecology >New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic?
【24h】

New Success With Microbicides and Pre-Exposure Prophylaxis for Human Immunodeficiency Virus (HIV): Is Female-Controlled Prevention the Answer to the HIV Epidemic?

机译:杀菌剂和人类免疫缺陷病毒(HIV)的暴露前预防的新成功:由女性控制的预防是HIV流行的答案吗?

获取原文
           

摘要

Women who cannot negotiate condom use with their partners, often due to socioeconomic factors and sexual abuse, have no means of preventing themselves from acquiring the human immunodeficiency virus (HIV). There is a need to develop HIV-preventive methods initiated and controlled by women. Microbicides and other pre-exposure prophylaxis may help fill that need. Although two decades of research on broad-spectrum microbicides have generally been disappointing, recent trials with HIV-specific agents have yielded promising initial results. A new era of clinical research involves novel biochemical prevention methods, including HIV-specific vaginal microbicides and oral antiretroviral chemoprophylaxis drugs (pre-exposure prophylaxis; PrEP) that may help provide more control for women.
机译:经常由于社会经济因素和性虐待而无法与伴侣协商使用安全套的妇女无法阻止自己获得人类免疫缺陷病毒(HIV)。有必要发展由妇女发起和控制的艾滋病毒预防方法。杀菌剂和其他暴露前预防措施可能有助于满足这一需求。尽管对广谱杀微生物剂的二十年研究通常令人失望,但最近针对HIV特异性药剂的试验已产生了令人鼓舞的初步结果。临床研究的新纪元涉及新颖的生化预防方法,包括HIV特异的阴道杀菌剂和口服抗逆转录病毒化学预防药物(暴露前预防; PrEP),可帮助女性更好地控制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号